31/10/2025
New Frontiers in Alzheimer's Treatment š
For years, Alzheimer's treatments mainly concentrated on managing symptoms by temporarily boosting neurotransmitter activity (e.g., Cholinesterase Inhibitors). Yet, recent breakthroughs offer new hope by targeting the disease's underlying pathology.
Disease-Modifying Therapies (DMTs), such as monoclonal antibodies (like lecanemab and donanemab), represent a major advancement. These treatments are designed to use the immune system to actively remove the toxic beta-amyloid protein deposits (plaques) from the brain. Clinical trials have demonstrated these anti-amyloid therapies can modestly slow the progression of cognitive decline in individuals with early-stage Alzheimer's disease.
Researchers are also exploring completely new approaches. This includes examining the connection between insulin resistance and brain function, sometimes referring to Alzheimer's as "Type 3 Diabetes," and testing existing drugs like Semaglutide to see if they can slow disease progression. Another area of focus is activating the brainās natural "cleanup crew" immune cells, or microglia, to clear away debris and plaques.
š” Key Takeaway: Newer treatments are targeting the disease's root cause, offering a path to slowing progression.
Access the full blogs associated with these posts on the HUB, the IPS website : https://lnkd.in/g3uqxUHP
For more information, talk to EVE, our information bot or contact our friendly team at support@infectioncontrol.care
This link will take you to a page thatās not on LinkedIn